
Chemical and Pharmaceutical Bulletin p. 1130 - 1134 (1998)
Update date:2022-08-03
Topics:
Baba, Atsuo
Makino, Haruhiko
Ohta, Yoshikazu
Sohda, Takashi
The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2- (1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (1, TAK-603), which is under clinical evaluation as a new type of disease-modifying antirheumatic drug (DMARD), were prepared to confirm th
View MoreChengdu Aslee Biopharmaceuticals, Inc
Contact:18608018419
Address:Chengdu Aslee Biopharmaceuticals, Inc
Contact:886 2 2541 0022
Address:8 Fl., No. 11, Sec. 1, Chung Shan North Rd., Taipei, Taiwan R.O.C.
Shantou Baokang Pharmaceutical Co., Ltd.
Contact:+86-754-88873487
Address:5/F B Block Huangshan Bldg Huangshan Rd Shantou
Tianjin Pharmacn Medical Technology Co.,Ltd.
Contact:86-22-60122566ext.866(English),23359620
Address:Green Industrial Base, 6 Haitaifazhan Sixth Rd., Huayuan Industrial Area, Tianjin, 300384, China
Shao Xing Empire Import&Export CO.,ltd
Contact:86-575-82127757
Address:11#, Weiwu Road, Shangyu Industrial Park, Hangzhou Bay, Hangzhou, Zhejiang Province, China
Doi:10.1039/c6cc05707a
(2016)Doi:10.1039/a802797h
(1998)Doi:10.1039/a801922c
(1998)Doi:10.1021/jo01046a525
(1963)Doi:10.1016/j.jfluchem.2005.03.020
(2005)Doi:10.1055/s-2006-950244
(2006)